Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1797
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
aliskiren
Sponsor
Novartis